The startup develops injectable insulin and glucagon formulations for diabetes management, focusing on a bi-hormonal pump that delivers both hormones simultaneously. This technology enables healthcare providers to offer more effective and personalized treatment options for diabetic patients.
Funding
Funding not disclosed
Founders
Product
Problem
Diabetes management often requires precise balancing of insulin and glucagon levels, a process made difficult by the separate delivery mechanisms and varying absorption rates of current treatments. This can lead to unpredictable blood glucose levels, increasing the risk of both hyperglycemia and hypoglycemia.
Solution
Casspharma is developing co-formulated, rapid-acting injectable insulin and glucagon treatments designed to work together, providing a more balanced and responsive approach to managing blood glucose. Their primary focus is on a bi-hormonal pump that delivers both hormones simultaneously, mimicking the natural pancreatic response. This technology aims to give diabetic patients and their healthcare providers more precise control over blood sugar levels, reducing the frequency and severity of glycemic excursions. By combining insulin and glucagon in a single delivery system, Casspharma seeks to improve the overall safety and efficacy of diabetes management.
Target Audience
The primary target audience includes individuals with Type 1 and Type 2 diabetes who require insulin therapy, as well as endocrinologists and other healthcare providers specializing in diabetes management.
Features
- Co-formulated rapid-acting insulin and glucagon for simultaneous delivery
- Bi-hormonal pump designed to mimic natural pancreatic hormone release
- Potential for improved glycemic control and reduced risk of hypoglycemia
- Enhanced precision in insulin and glucagon dosing